Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

This Phase 3 clinical trial is testing whether adding ribociclib — a drug that targets cancer cell growth — combined with an aromatase inhibitor improves outcomes for women with hormone receptor-positive, HER2-negative early breast cancer who still had cancer remaining after chemotherapy before surgery. Women aged 18 and older who have completed neoadjuvant chemotherapy and have residual invasive breast cancer may be eligible, provided they have not previously received a CDK4/6 inhibitor and meet specific heart and organ function criteria. Participation involves taking daily oral tablets and attending clinic visits for safety monitoring and imaging scans over several years. This summary was prepared to help patients understand the study in plain language.